Stockscreener 앱 받기
4.82
1.90%
0.09
Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스
AVIR|Atea Pharmaceuticals Inc|Price:4.810|Chg%:+0.080 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus - European AIDS Treatment Group
Atea Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AVIR - TradingView
AVIR|Atea Pharmaceuticals Inc|Price:4.730|Chg%:-0.020 - TradingKey
Atea Pharmaceuticals Inc (AVIR) Cash Flow - TradingKey
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy - TipRanks
Atea Pharmaceuticals (AVIR) Faces Modest Decline Near Key Support LevelIchimoku Kumo Twist - dars.gov.et
Atea Pharmaceuticals Starts Phase 1 AT-587 Trial - t.co
William Blair Maintains Atea Pharmaceuticals(AVIR.US) With Buy Rating - Moomoo
Atea begins phase 1 trial of hepatitis E treatment AT-587 - Investing.com UK
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
Hepatitis E Has No Approved Treatments as Atea Begins Human Trial - Stock Titan
AVIR Q1 2026 Earnings: Narrower-than-expected Loss Drives Modest Stock GainCost Structure Review - DonanımHaber
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) Proxy filing Summary - Quartr
Atea Pharmaceuticals (AVIR) Q4 2025 earnings summary - Quartr
Atea Pharmaceuticals (AVIR) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary - Quartr
Atea Pharmaceuticals (AVIR) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Atea Pharmaceuticals (AVIR) AGM 2026 Summary - Quartr
Atea Pharmaceuticals (AVIR) Q2 2024 earnings summary - Quartr
Atea Pharmaceuticals Inc (AVIR:UW): Stock Price, Quote and News - BNN Bloomberg
AVIRAtea Pharmaceuticals Inc Short Interest - Finviz
Atea Pharmaceuticals Gains 2.67% as Stock Approaches Key Resistance LevelMoney Flow Index - dars.gov.et
Atea Pharmaceuticals (AVIR) Q1 2026 Earnings: Beat on EPS Despite Pre-Revenue Status; Stock Climbs 2.67%Consensus Forecast Report - dars.gov.et
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Enterprise value to EBIT forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to sales forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Atea Pharmaceuticals Inc (AVIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (NASDAQ:AVIR) Refocuses Antiviral Pipeline - Kalkine Media
Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR) - TradingView
AVIR Forecast — Price Target — Prediction for 2027 - TradingView
Atea completes enrollment in phase 3 hepatitis C trial By Investing.com - Investing.com Australia
Atea completes enrollment in phase 3 hepatitis C trial - Investing.com UK
Atea Pharmaceuticals Completes Patient Enrollment in Phase - GlobeNewswire
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - Sahm
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Nigeria
Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs - Stock Titan
[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Equity awards boost Atea (AVIR) director Barbara Duncan’s holdings - Stock Titan
Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR) - Stock Titan
Atea Pharmaceuticals (AVIR) director receives new options and RSU awards - Stock Titan
Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):